Cytokinetics (CYTK) Operating Leases (2018 - 2026)
Cytokinetics (CYTK) posted quarterly Operating Leases of $105.2 million for Q1 2026, down 7.16% year-over-year from $113.4 million in Q1 2025, and down 2.53% quarter-over-quarter from $108.0 million in Q4 2025.
Cytokinetics (CYTK) Operating Leases (2018 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Operating Leases for 9 consecutive years, with $105.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 7.16% year-over-year to $105.2 million; the TTM figure through Mar 2026 stood at $105.2 million (down 7.16% YoY), while the FY2025 annual figure was $108.0 million, down 4.1% from the prior year.
- Operating Leases slipped to $105.2 million in Q1 2026 per CYTK's latest filing, from $108.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $126.9 million in Q4 2022 and bottomed at $105.2 million in Q1 2026.
- Historically, Operating Leases has averaged $115.8 million across 5 years, with a median of $114.4 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Leases soared 31.33% — and 2026, when it slipped 7.16%.
- Cytokinetics' Operating Leases stood at $126.9 million in 2022, then declined by 5.1% to $120.4 million in 2023, then dropped by 6.51% to $112.6 million in 2024, then dropped by 4.1% to $108.0 million in 2025, then declined by 2.53% to $105.2 million in 2026.
- Business Quant data shows CYTK's Operating Leases at $105.2 million in Q1 2026, $108.0 million in Q4 2025, and $110.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.43 Mn |
| Mar 31, 2026 | 105.24 Mn |
| Dec 31, 2025 | 107.97 Mn |
| Sep 30, 2025 | 110.66 Mn |
| Jun 30, 2025 | 111.03 Mn |
| Mar 31, 2025 | 113.35 Mn |
| Dec 31, 2024 | 112.58 Mn |
| Sep 30, 2024 | 114.75 Mn |
| Jun 30, 2024 | 116.72 Mn |
| Mar 31, 2024 | 118.55 Mn |
| Dec 31, 2023 | 120.43 Mn |
| Sep 30, 2023 | 122.22 Mn |
| Jun 30, 2023 | 123.83 Mn |
| Mar 31, 2023 | 125.34 Mn |
| Dec 31, 2022 | 126.90 Mn |
| Sep 30, 2022 | 114.41 Mn |
| Jun 30, 2022 | 112.73 Mn |
| Mar 31, 2022 | 112.02 Mn |
| Dec 31, 2021 | 112.23 Mn |
| Mar 31, 2021 | 85.30 Mn |